Preclinical Data Announcement
The Israel-based biotechnology company on Wednesday announced preclinical test data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved intranasal naloxone spray currently on the market.
Using an ex-vivo rabbit nasal mucosa model, researchers applied each formulation to mucosal tissue and washed it with Simulated Nasal Electrolyte Solution over a 30-minute period.
Compared with the commercial product, Polyrizon’s Trap and Target hydrogel showed higher fluorescence marker values, with differences reaching statistical significance (p < 0.0001, two-way ANOVA).
Company Statement
Tomer Izraeli, CEO of Polyrizon, said, “The ability to significantly outperform an existing marketed product in mucoadhesion is an important milestone as we continue advancing our Naloxone program.”
Manufacturing Milestone
Polyrizon also reached a major manufacturing upscaling milestone for its nasal-spray platform, moving from small-batch laboratory production to larger-scale controlled manufacturing to validate key parameters of its PL-14, a proprietary bio-adhesive formulation.
Stock Performance
PLRZ is down 99.74% year-to-date but has rebounded 45.88% over the past six months. The company has a market capitalization of $7.39 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.